Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA3 | O75311 | 1/20 | 0.46 |
| ▸ | GLRB | P48167 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.41 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2527622 | 0.82 | GLRA3 (0.68) | GLRA3GLRBHDAC4LTA4HKDM4E | |
| SCHEMBL20256885 | 0.81 | GLRA3 (0.49) | GLRA3GLRBHPGDSHDAC4LTA4H | |
| SCHEMBL10212048 | 0.78 | GLRA3 (0.43) | GLRA3GLRBGABRPGABRDGABRA1 | |
| SCHEMBL475508 | 0.78 | GLRA3 (0.70) | GLRA3GLRBHPGDSHDAC4LTA4H | |
| SCHEMBL19928407 | 0.78 | GLRA3 (0.46) | GLRA3GLRBHPGDSHDAC4LTA4H | |
| SCHEMBL15131324 | 0.78 | GLRA3 (0.46) | GLRA3GLRBHPGDSHDAC4LTA4H | |
| SCHEMBL3640416 | 0.77 | GLRA3 (0.50) | GLRA3GLRBHPGDSHDAC4LTA4H | |
| SCHEMBL16635585 | 0.77 | HPGDS (0.38) | GLRA3GLRBHPGDSHDAC4LTA4H | |
| SCHEMBL3941218 | 0.77 | GLRA3 (0.42) | GLRA3GLRBHPGDSLTA4HALDH1A1 | |
| SCHEMBL2987594 | 0.77 | DHODH (0.50) | GLRA3GLRBHPGDSLTA4HKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2046761-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| WO-2008009750-A2 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312370-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | GLRA3 3928/4885GLRB 1655/4885GABRP 317/4885 |
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | GLRA3 3696/4885GLRB 1381/4885GABRP 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.